<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809847</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-CLL-X4-054</org_study_id>
    <secondary_id>2012-001947-31</secondary_id>
    <nct_id>NCT01809847</nct_id>
  </id_info>
  <brief_title>Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation</brief_title>
  <official_title>Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation(CLL-X4 Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the safety and efficacy of anti-CD20 blockade with ofatumumab in the context of&#xD;
      allogeneic HCT in CLL&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the study is to investigate the safety and efficacy of a consequent anti-CD20&#xD;
      therapy with the antibody ofatumumab in the context of allogeneic HCT. Allogeneic HCT itself&#xD;
      is not a study intervention and is triggered by the availability of an HLA-compatible stem&#xD;
      cell donor. The study is divided into an induction part and a maintenance part. During&#xD;
      induction where the antibody is combined with high dose dexamethasone, the main goal is to&#xD;
      reduce the tumor load prior to allogeneic HCT. Patients who achieved disease control (CR, PR&#xD;
      and SD) by the antibody proceed to maintenance therapy with the antibody. Patients with&#xD;
      progressive disease go off study. The idea behind maintenance therapy is that ofatumumab may&#xD;
      contribute to tumor control early after allogeneic stem cell transplantation while T-cell&#xD;
      based graft-versus leukemia effects are still not fully established. External tumor control&#xD;
      could lower the pressure to taper immunosuppressive drugs early after transplantation and&#xD;
      could thereby indirectly contribute to better GVHD-prophylaxis. Furthermore, anti-CD20&#xD;
      antibodies have proven activity in the treatment of chronic GVHD. In summary, the concept of&#xD;
      a consequent CD20 blockade in the context of allogeneic transplantation could result in&#xD;
      better leukemic control and better GVHD prophylaxis, which is a highly attractive goal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate after induction therapy</measure>
    <time_frame>week 9</time_frame>
    <description>efficacy analysis of anti-CD20 blockade with ofatumumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of MRD-negative patients</measure>
    <time_frame>baseline, week 9, month 14</time_frame>
    <description>rate of MRD-negative patients who did not experience relapse, progression or death within the first 14 months after study enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of allogeneic HCT</measure>
    <time_frame>month 9</time_frame>
    <description>Rate of patients who reach allogeneic HCT if HLA-matched donor is available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse drug reactions grade III/IV</measure>
    <time_frame>week 1 till week 9; month 4 till month 9; month 12; month 14; until 30 days after last administration of the study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall, event-, and progression free survival</measure>
    <time_frame>week 1 till week 9; month 4 till month 9; month 12; month 14; up to 5 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse incidence</measure>
    <time_frame>month 4 till month 9; month 12; month 14; up to 5 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-relapse mortality</measure>
    <time_frame>week 1 till week 9; month 4 till month 9; month 12; month 14; up to 5 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of acute and chronic GVHD</measure>
    <time_frame>during maintenance therapy; month 12, month 14; up to 5 years follow-up</time_frame>
    <description>provided that allogeneic HCT was conducted</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Lymphatic Leukemia</condition>
  <arm_group>
    <arm_group_label>Ofatumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose of 300 mg Ofatumumab followed by seven weekly infusions of 2000 mg. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab</intervention_name>
    <description>Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.&#xD;
An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy.</description>
    <arm_group_label>Ofatumumab</arm_group_label>
    <other_name>Arzerra</other_name>
    <other_name>Anti-CD20 antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of CLL according to WHO criteria (Hallek 2008) confirmed by flow cytometry&#xD;
             of peripheral blood or bone marrow&#xD;
&#xD;
          -  Age &gt; 55 years&#xD;
&#xD;
          -  Poor-risk disease according to the EBMT CLL Transplant Consensus&#xD;
&#xD;
               -  Non-response or early relapse (within 12 months) after purine analogue-containing&#xD;
                  therapy&#xD;
&#xD;
               -  Relapse (within 24 months) after purine analogue combination therapy or treatment&#xD;
                  of similar efficacy (ie, autologous stem cell transplantation)&#xD;
&#xD;
               -  p53 deletion/mutation (del 17p-) requiring treatment&#xD;
&#xD;
          -  Measurable disease in the peripheral blood defined by a minimum clonal lymphocyte&#xD;
             count of 0.5 GPT/L at the time of study inclusion&#xD;
&#xD;
          -  Medically fit patients eligible for allogeneic HCT&#xD;
&#xD;
          -  Informed consent for related and unrelated donor search and the goal to perform&#xD;
             allogeneic HCT&#xD;
&#xD;
          -  Sexually mature males must agree to use adequate and medically accepted method of&#xD;
             contraception throughout the study if their sexual partners are woman of child bearing&#xD;
             potential (WOCBP) WOCBP must be using an adequate and medically accepted method of&#xD;
             contraception to avoid pregnancy throughout the study and for at least 3 months after&#xD;
             the study.&#xD;
&#xD;
          -  WOCBP includes any female that has experienced menarche and who has not undergone&#xD;
             successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral&#xD;
             oophorectomy) or is not postmenopausal (defined as amenorrhea &gt;12 consecutive months);&#xD;
             or woman on hormone replacement therapy (HRT) with documented serum follicle&#xD;
             stimulating hormone (FSH) level &gt;35mlU/mL.&#xD;
&#xD;
          -  WOCBP must have a negative serum or urine pregnancy test prior to the start of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Richter's transformation in current relapse or active disease&#xD;
&#xD;
          -  Prior allogeneic HCT&#xD;
&#xD;
          -  Treatment with any known non-marketed drug substance or experimental therapy within 5&#xD;
             terminal half lives or 4 weeks prior to enrollment, whichever is longer, or&#xD;
             participation in any other interventional clinical study&#xD;
&#xD;
          -  Non-response to monotherapy with ofatumumab prior to study inclusion&#xD;
&#xD;
          -  Clinically significant cardiac disease including unstable angina, acute myocardial&#xD;
             infarction within six months prior to randomization, congestive heart failure (left&#xD;
             ventricular ejection fraction &lt; 50%)&#xD;
&#xD;
          -  Abnormal renal function defined by an estimated GFR &lt; 50 ml/min&#xD;
&#xD;
          -  Abnormal lung function tests defined by a DLCO &lt;50%, FEV1%VC &lt;70% despite appropriate&#xD;
             treatment&#xD;
&#xD;
          -  Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg or HBcAb&#xD;
&#xD;
          -  Positive serology for hepatitis C (HC) defined as a positive test for anti-HCV,&#xD;
             confirmed by PCR&#xD;
&#xD;
          -  Screening laboratory values:&#xD;
&#xD;
               -  total bilirubin &gt;1.5 times upper normal limit (unless due to AIHA or a known&#xD;
                  history of Gilbert's disease)&#xD;
&#xD;
               -  ALT or AST &gt;2.5 times upper normal limit&#xD;
&#xD;
               -  Gamma glutamyl transpeptidase (GGT) &gt;2.5 times upper normal limit (unless due to&#xD;
                  disease involvement of the liver)&#xD;
&#xD;
          -  Other past or current hematologic or solid organ malignancy. Subjects who have been&#xD;
             free of malignancy for at least 3 years, or have a history of completely resected&#xD;
             non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible.&#xD;
&#xD;
          -  Male subjects unable or unwilling to use adequate contraception methods from study&#xD;
             start to one year after the last dose of protocol therapy.&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Significant concurrent, uncontrolled medical condition including, but not limited to,&#xD;
             renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or&#xD;
             psychiatric disease which in the opinion of the investigator may represent a risk for&#xD;
             the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>56 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Schetelig, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, 01307 Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum München Schwabing</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) GmbH</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <state>Brandenburg</state>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsche Klinik für Diagnostik</name>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes Gutenberg Universität</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz GmbH</name>
      <address>
        <city>Chemnitz</city>
        <state>Sachsen</state>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.sal-aml.org</url>
    <description>Website Study Alliance Leukemia (coordinating study group)</description>
  </link>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>March 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2013</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>Chronic Lymphatic Leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>HLA</keyword>
  <keyword>Histocompatibility</keyword>
  <keyword>HCT</keyword>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <keyword>Ofatumumab</keyword>
  <keyword>CD20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofatumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

